OpiCalc Logo

OpiCalc

989 Clinical Tools

Logo
OpiCalc
7-Point Dermoscopy ChecklistABSI (Burn Severity)AGEP ScoreAJCC Melanoma StagingALDEN AlgorithmBWH SCC StagingBody Surface Area (BSA)Breslow & Clark MicrostagingCTCAE Skin ToxicityDLQIEASI ScoreGAGS (Acne)HiSCRIGAIHS4Lund-Browder ChartMSK Melanoma NomogramMelanoma Risk ScreeningPASI ScorePOEMRegiSCAR DRESS ValidationRevised Baux ScoreSCORADmPASI
OpiCalc Logo

OpiCalc

Open-access clinical infrastructure. Built to the standard every clinician deserves — fast, private, and free.

Zero data stored
Always free
Our mission & transparency

Get in Touch

Tool request, clinical feedback, or partnership inquiry — we read everything.

WhatsApp feedback
Email us
Partnership inquiry

© 2026 OpiCalc • Calculated Care

ProtocolsAboutPrivacyTerms

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).
0%0%100%

erythema

edema

crusting

excoriation

lichenification

dryness

0010
0010
Guidelines & Evidence

Clinical Details

Section 1

When to Use

When to Use

Evaluating the severity of atopic dermatitis (eczema) objectively.
Monitoring disease progression and treatment response over time.
Standardized reporting in clinical trials for atopic dermatitis therapies.
Section 2

Formula & Logic

Formula

SCORAD = (A/5) + (7B/2) + C

Variables

A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.
Section 3

Pearls/Pitfalls

Clinical Pearls

Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
A score > 50 indicates severe atopic dermatitis.
Section 4

Next Steps

Interpretation

< 25: Mild disease.
25 - 50: Moderate disease.
> 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.
Section 5

Evidence Appraisal

Last Comprehensive Review: 2026

Related Dermatology Tools

DLQI
EASI Score
GAGS
HiSCR
IGA
IHS4
Lund-Browder Chart
Melanoma Risk Screening
mPASI
MSK Melanoma Nomogram
Have feedback about this calculator?Let us know.